Top Page
OrganiGram Holdings
(NASDAQ:OGI)
OrganiGram Holdings (OGI) vs. iShares MSCI Canada ETF (EWC)
OrganiGram Holdings Business Overview & Revenue Model
OrganiGram Holdings Earnings Call Summary
OrganiGram Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 223.82M | 159.84M | 149.21M | 145.81M | 79.16M | 86.80M |
| Gross Profit | 75.59M | 47.52M | 35.07M | 31.57M | -28.40M | -56.49M |
| EBITDA | 3.80M | -23.59M | -207.62M | 10.96M | -95.59M | -121.47M |
| Net Income | 7.77M | -45.44M | -229.48M | -14.28M | -130.70M | -136.16M |
Balance Sheet | ||||||
| Total Assets | 564.62M | 407.86M | 298.45M | 577.11M | 554.02M | 417.62M |
| Cash, Cash Equivalents and Short-Term Investments | 36.78M | 107.57M | 33.86M | 98.91M | 183.84M | 74.73M |
| Total Debt | 9.15M | 4.46M | 4.72M | 3.36M | 4.96M | 103.67M |
| Total Liabilities | 179.12M | 101.87M | 26.83M | 69.05M | 74.21M | 118.10M |
| Stockholders Equity | 385.50M | 305.99M | 271.62M | 508.06M | 479.81M | 299.53M |
Cash Flow | ||||||
| Free Cash Flow | -16.95M | -1.47M | -62.70M | -84.99M | -40.92M | -123.78M |
| Operating Cash Flow | 2.75M | 3.87M | -35.80M | -36.21M | -28.59M | -45.13M |
| Investing Cash Flow | -103.69M | -38.77M | 1.35M | 44.03M | -115.11M | -138.20M |
| Financing Cash Flow | 80.91M | 107.78M | -817.00K | 5.33M | 174.46M | 160.37M |
OrganiGram Holdings Technical Analysis
OrganiGram Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | C$1.35B | 52.06 | 1.73% | ― | 31.72% | ― | |
| ― | C$304.92M | 75.67 | 1.86% | ― | 38.86% | ― | |
| ― | C$1.94B | ― | -12.60% | ― | 4.92% | -64.84% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | C$392.92M | ― | -0.70% | ― | 28.42% | 48.33% | |
| ― | C$3.03B | ― | -24.93% | ― | -2.64% | 1.65% | |
| ― | C$620.45M | ― | -98.42% | ― | -4.24% | 55.82% |
OrganiGram Holdings Corporate Events
Organigram Global Inc. has released polling data indicating that a majority of Canadians believe the federal government should modernize its cannabis policy, viewing the legal cannabis industry as a significant economic opportunity. The poll suggests that Canadians want the government to support job creation and innovation in the cannabis sector, reduce excise taxes for legal producers, and combat the illicit market. The findings highlight a shift in public perception, with cannabis now seen as a mainstream and integral part of Canada’s economic landscape, contributing significantly to GDP and employment.
The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$2.50 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.
Organigram Global Inc. has announced that CEO Beena Goldenberg will extend her tenure until November 30, 2025, to facilitate the completion of the company’s CEO search process. The board is pleased with the progress in finding a leader aligned with the company’s strategic vision and growth objectives. Goldenberg will continue to oversee daily operations, ensuring continuity and momentum across business lines, while the company remains focused on delivering key priorities and creating long-term shareholder value.
The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.
Organigram Global Inc. has launched ‘happly,’ a new U.S. hemp-derived THC brand featuring FAST™ nanoemulsion gummies designed for specific mood states: socializing, relaxation, and sleep. This launch marks Organigram’s continued expansion into the U.S. market, targeting the growing segment of consumers interested in ‘mindful recreation’ with low-dose THC products. The brand aims to offer consumers moderation, control, and predictability in their cannabis experiences, using proprietary technology to ensure consistent effects. This strategic move underscores Organigram’s commitment to innovation and positions the company to capitalize on the increasing demand for functional cannabinoid products.
The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.
Organigram Global Inc. has released a report highlighting the significant economic impact of Canada’s legal cannabis industry, which contributed over $16 billion to the national GDP in 2024. The industry supports over 227,000 jobs and has surpassed traditional sectors like forestry and breweries in economic contribution. Despite its success, outdated policies and tax structures are hindering further growth and export potential, with calls for modernization to fully leverage Canada’s first-mover advantage in the global cannabis market.
The most recent analyst rating on (TSE:OGI) stock is a Hold with a C$2.00 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.
OrganiGram Holdings recently held its earnings call, revealing a strong quarter characterized by record-breaking revenue and a robust market presence in Canada. Despite facing challenges such as ERP integration issues and delays in EU GMP certification, the company remains optimistic about its long-term growth trajectory, supported by positive cash flow and strategic initiatives.
OrganiGram Holdings, a leading cannabis company in Canada, is renowned for its production of high-quality, indoor-grown cannabis for both medical and recreational use, with a focus on expanding its international footprint.
Organigram Holdings reported record financial results for the third quarter of fiscal 2025, with significant increases in revenue and adjusted EBITDA. The company achieved a 72% year-over-year increase in net revenue, driven by the acquisition of Motif Labs and international sales growth. Organigram’s strategic expansion into the U.S. market and its leadership in the Canadian cannabis sector underscore its ambition to become a global player. Despite a net loss due to changes in financial instruments, the company continues to optimize its operations and expand its brand portfolio, aiming for further international growth.
The most recent analyst rating on (TSE:OGI) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.
Organigram Global Inc. announced it will release its third quarter fiscal 2025 earnings results on August 13, 2025. The company will host a conference call to discuss these results, reflecting its continued focus on market leadership and expansion in the cannabis industry. This announcement underscores Organigram’s commitment to transparency and stakeholder engagement, potentially impacting its market positioning and investor relations.
The most recent analyst rating on (TSE:OGI) stock is a Buy with a C$3.00 price target. To see the full list of analyst forecasts on OrganiGram Holdings stock, see the TSE:OGI Stock Forecast page.